Abstract
The effective treatment of pneumonia in a critical care setting involves optimal administration of antibiotics. Various micro-organisms are responsible for causing pneumonia. As the pathogen may not always be evident, empiric broad spectrum antibiotic regimens are often used. There are various resources available to guide antibiotic therapy but unfortunately these have not been validated in critically ill patients. Of increasing concern, multidrug resistant bacteria are becoming more prevalent in the critical care units causing a paradigm shift for antibiotic therapy. In the context of a diminishing pipeline of antibiotic development, optimal use of available antibiotics is essential. Alternative modes of administration such as aerosolisation should be considered especially in nosocomial, multidrug resistant organisms. Further to this, de-escalation of antibiotics and antibiotic cycling are some of the strategies that can be utilised to reduce the emergence of multidrug resistant bacteria. Improvement of clinical outcomes for pneumonia in critical care may also be achieved through use of therapeutic drug monitoring and combination therapy. We advocate that the rational development of local antibiograms for critical care units to better guide the empiric antibiotic therapy in these patients.
Keywords: Aerosolisation, antibiotic, antibiotic cycling, dosing, pharmacokinetics, pharmacodynamics, pneumonia, tissue penetration, Various micro-organisms, antibiotic therapy
Current Respiratory Medicine Reviews
Title:Antibiotic Therapy of Pneumonia in Critical Care
Volume: 8 Issue: 3
Author(s): Jayesh Dhanani, Jason A Roberts and Jeffrey Lipman
Affiliation:
Keywords: Aerosolisation, antibiotic, antibiotic cycling, dosing, pharmacokinetics, pharmacodynamics, pneumonia, tissue penetration, Various micro-organisms, antibiotic therapy
Abstract: The effective treatment of pneumonia in a critical care setting involves optimal administration of antibiotics. Various micro-organisms are responsible for causing pneumonia. As the pathogen may not always be evident, empiric broad spectrum antibiotic regimens are often used. There are various resources available to guide antibiotic therapy but unfortunately these have not been validated in critically ill patients. Of increasing concern, multidrug resistant bacteria are becoming more prevalent in the critical care units causing a paradigm shift for antibiotic therapy. In the context of a diminishing pipeline of antibiotic development, optimal use of available antibiotics is essential. Alternative modes of administration such as aerosolisation should be considered especially in nosocomial, multidrug resistant organisms. Further to this, de-escalation of antibiotics and antibiotic cycling are some of the strategies that can be utilised to reduce the emergence of multidrug resistant bacteria. Improvement of clinical outcomes for pneumonia in critical care may also be achieved through use of therapeutic drug monitoring and combination therapy. We advocate that the rational development of local antibiograms for critical care units to better guide the empiric antibiotic therapy in these patients.
Export Options
About this article
Cite this article as:
Dhanani Jayesh, A Roberts Jason and Lipman Jeffrey, Antibiotic Therapy of Pneumonia in Critical Care, Current Respiratory Medicine Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339812800493232
DOI https://dx.doi.org/10.2174/157339812800493232 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Nano-vaccination Strategies: Applications and Challenges for Intranasal Immunization
Current Pharmaceutical Biotechnology Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry GluVII:06 - A Highly Conserved and Selective Anchor Point for Non-Peptide Ligands in Chemokine Receptors
Current Topics in Medicinal Chemistry Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Advancement of Prodrug Approaches for Nucleotide Antiviral Agents
Current Topics in Medicinal Chemistry Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Novel Heterocyclic Fluoroquinolone Citrate Conjugates as Potential Inhibitors of Topoisomerase IV: A Computational Molecular Modeling Study
Current Drug Discovery Technologies Synthesis of Dihydrazones as Potential Anticancer and DNA Binding Candidates: A Validation by Molecular Docking Studies
Anti-Cancer Agents in Medicinal Chemistry COVID-19 in Children: A Narrative Review
Current Pediatric Reviews Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors
Current Medicinal Chemistry Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome<sup>#</sup>
Current Pharmaceutical Design Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Current Topics in Medicinal Chemistry New Inhibitors of Glycogen Phosphorylase as Potential Antidiabetic Agents
Current Medicinal Chemistry Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents New Prospects for Drug Discovery from Structural Studies of Rhodopsin
Current Pharmaceutical Design Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I)
Current Pharmaceutical Design Bioinformatics Analysis to Identify Intersection Genes, Associated Pathways and Therapeutic Drugs between COVID-19 and Oral Candidiasis
Combinatorial Chemistry & High Throughput Screening